Human Systems Biology Laboratory, Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico.
Programa de Doctorado en Ciencias Biológicas, UNAM, Mexico City, Mexico.
Front Immunol. 2021 Sep 16;12:705646. doi: 10.3389/fimmu.2021.705646. eCollection 2021.
COVID-19 is a disease with a spectrum of clinical responses ranging from moderate to critical. To study and control its effects, a large number of researchers are focused on two substantial aims. On the one hand, the discovery of diverse biomarkers to classify and potentially anticipate the disease severity of patients. These biomarkers could serve as a medical criterion to prioritize attention to those patients with higher prone to severe responses. On the other hand, understanding how the immune system orchestrates its responses in this spectrum of disease severities is a fundamental issue required to design new and optimized therapeutic strategies. In this work, using single-cell RNAseq of bronchoalveolar lavage fluid of nine patients with COVID-19 and three healthy controls, we contribute to both aspects. First, we presented computational supervised machine-learning models with high accuracy in classifying the disease severity (moderate and severe) in patients with COVID-19 starting from single-cell data from bronchoalveolar lavage fluid. Second, we identified regulatory mechanisms from the heterogeneous cell populations in the lungs microenvironment that correlated with different clinical responses. Given the results, patients with moderate COVID-19 symptoms showed an activation/inactivation profile for their analyzed cells leading to a sequential and innocuous immune response. In comparison, severe patients might be promoting cytotoxic and pro-inflammatory responses in a systemic fashion involving epithelial and immune cells without the possibility to develop viral clearance and immune memory. Consequently, we present an in-depth landscape analysis of how transcriptional factors and pathways from these heterogeneous populations can regulate their expression to promote or restrain an effective immune response directly linked to the patients prognosis.
COVID-19 是一种临床表现范围从轻度到重度的疾病。为了研究和控制其影响,大量研究人员专注于两个重要目标。一方面,发现多样化的生物标志物来对患者的疾病严重程度进行分类并可能进行预测。这些生物标志物可以作为医学标准,优先关注那些更有可能出现严重反应的患者。另一方面,了解免疫系统在疾病严重程度谱中如何协调其反应是设计新的和优化治疗策略的基本问题。在这项工作中,我们使用了来自 9 名 COVID-19 患者和 3 名健康对照者的支气管肺泡灌洗液的单细胞 RNAseq,为这两个方面做出了贡献。首先,我们使用计算监督机器学习模型,从支气管肺泡灌洗液的单细胞数据中,以高精度对 COVID-19 患者的疾病严重程度(中度和重度)进行分类。其次,我们从肺部微环境中的异质细胞群中确定了与不同临床反应相关的调节机制。鉴于这些结果,中度 COVID-19 症状的患者表现出其分析细胞的激活/失活特征,导致连续的、无害的免疫反应。相比之下,严重患者可能会以系统性方式促进细胞毒性和促炎反应,涉及上皮细胞和免疫细胞,而没有可能清除病毒和产生免疫记忆的可能性。因此,我们对这些异质群体中的转录因子和途径如何调节其表达以促进或抑制与患者预后直接相关的有效免疫反应进行了深入的全景分析。